Ibrutinib-Rituximab and FCR Show Comparable HRQOL in Frontline CLL

Continuous treatment with ibrutinib (Imbruvica) plus rituximab (Rituxan) did not compromise health-related quality of life (HRQOL) compared with fludarabine, cyclophosphamide, and rituximab (FCR) over 4 years of follow-up in patients with previously untreated chronic lymphocytic leukemia (CLL), according to secondary end point data from the phase 3 FLAIR trial (EudraCT: 2013-001944-76) published in the British Journal of Haematology.¹

Of 771 patients enrolled in the FLAIR trial, 651 (84.4%) completed 3 validated patient-reported outcome (PRO) questionnaires at baseline and at prespecified follow-up intervals, constituting the intention-to-treat PRO population (ibrutinib-rituximab, n = 329; FCR, n = 322). The median patient age was 63 years (range, 27-76); most patients were male (ibrutinib-rituximab, 74.5%; FCR, 72.0%) and White (95%).

Despite the substantially different treatment durations administered—up to 6 years of continuous ibrutinib-rituximab vs 6 fixed cycles of FCR—HRQOL trajectories were broadly similar between arms across all PRO instruments assessed, including the EORTC-QLQ-C30, QLQ CLL Module (QLQ-CLL16), 3-level EQ-5D, and EQ5D visual analogue. Importantly, none of the statistically significant between-group differences detected exceeded the minimally important threshold for clinical meaningfulness.

FCR-treated patients showed notably worse scores on physical, role, and social functioning scales at the end of treatment, with recovery to levels comparable to the ibrutinib-rituximab group by 12 to 18 months. A similar pattern was observed for fatigue on both the QLQ-C30 and QLQ-CLL16 scales, with FCR-group scores declining to match the ibrutinib-rituximab group by 12 months and continuing to improve through month 36. By contrast, diarrhea scores were consistently higher in the ibrutinib-rituximab group than in the FCR group from the end of treatment through month 48, reflecting the known gastrointestinal toxicity profile of ibrutinib.

“Our results reflect the interplay between time-limited FCR in a young-fit patient group and continuous ibrutinib treatment, which, while efficacious, has a burden of toxicity,” authors Allsup et al reflected in their conclusion.¹ “Newer [Bruton tyrosine kinase inhibitors; BTKis] may have a more positive impact on QOL, as may time-limited combinations of novel agents delivered in a personali[z]ed approach with [minimal residual disease; MRD] monitoring.”

FLAIR Trial Design and Context

FLAIR was a phase 3, open-label, randomized controlled trial conducted across 101 National Health Service hospitals in the United Kingdom. Eligible patients were aged 18 to 75 years with a WHO performance status of 0 to 2, required treatment, and were fit for fludarabine-based chemoimmunotherapy. Patients with greater than 20% del(17p) were excluded. Participants were randomly assigned 1:1 to ibrutinib 420 mg/day orally for up to 6 years plus rituximab for 6 cycles, or FCR for 6 cycles.

The primary end point of FLAIR was progression-free survival (PFS). A prior interim analysis demonstrated significantly superior PFS for ibrutinib-rituximab vs FCR.² HRQOL was a prespecified secondary end point.

The authors acknowledged several limitations. Because HRQOL data were collected only through disease progression, the impact of relapse on long-term HRQOL remains unknown. Black patients comprised only 1% of the PRO cohort, below general UK population levels, limiting the generalizability of findings. The authors also noted that the validated instruments employed—developed in the chemoimmunotherapy era—may not be optimally sensitive to the symptom profile of contemporary targeted therapies. The updated EORTC QLQ-CLL17, which includes domains more relevant to BTKi therapy, may have detected more granular differences between regimens.

Clinical Implications

In their discussion, the authors characterized the minimal HRQOL differences as somewhat “counterintuitive” given that other studies of novel agents in CLL have demonstrated QOL advantages over chemoimmunotherapy. They attributed this, in part, to the relatively young, fit patient population enrolled in FLAIR, a group known to respond well to FCR and less likely to experience severe chemotherapy-related complications than older, more comorbid patients. The PFS benefits of continuous ibrutinib-rituximab, they suggested, may be partially offset by the long-term toxicity burden of ibrutinib, including cardiovascular and gastrointestinal effects, as evidenced by real-world discontinuation rates.

The authors noted that newer BTKis and time-limited combinations of novel agents guided by MRD monitoring may offer more favorable HRQOL profiles. A planned future QOL analysis comparing FCR, ibrutinib-rituximab, ibrutinib monotherapy, and ibrutinib-venetoclax (Venclexta) within the FLAIR platform trial is expected to provide additional insights.

REFERENCES

1. Allsup DJ, Cairns DA, Samy EF, et al. Patient‐reported health‐related quality of life in previously untreated chronic lymphocytic leukaemia: Results from the randomised phase 3 FLAIR trial comparing ibrutinib–rituximab versus fludarabine–cyclophosphamide–rituximab. British Journal of Haematology. 2026;208(5):1596-1607. doi:10.1111/bjh.70416

2. Hillmen P, Pitchford A, Bloor A, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):535-552. doi:10.1016/S1470-2045(23)00144-4